Second Genome, Inc.

Industry

  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Technologies
      • Genomics-Proteomics
    • Large Molecule
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Digital Health
  • Pharmaceuticals
    • Vaccines
  • Services
See more in Biomedtracker

Latest on Second Genome, Inc.

Scrip

Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs

 
• By Joseph Haas, Ian Haydock, and Jung Won Shin

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Alnylam And Dicerna Team Up

Scrip

Gilead Moves Into Microbiome In Deal With Second Genome

 
• By Joseph Haas

Gilead Sciences Inc. has been looking for a way into microbiome research for a while, and following a competitive process, settled on a four-year collaboration with Second Genome Inc. to identify b

Scrip

Interview: KoBioLabs Pioneering The Microbiome Landscape In Korea

 
• By Jung Won Shin

Amid a global boom in microbiome drug development in recent years, industry interest, R&D, and investment in this promising new therapeutic sector is also rising in South Korea. KoBioLabs Inc., founde

Scrip

Microbiome Clinical Studies Loom Large In 2018

 
• By John Davis

2018 looks set to be the year when the microbiome comes of age, clinically at least. Data are expected from early clinical studies using an array of approaches, which, if successful, will drive increa